The company’s Keytruda cancer treatment medication is doing well, and the introduction of Winrevair, a medication for pulmonary arterial hypertension (PAH), is also helping to increase revenue ...

Notably, Merck's Winrevair pulmonary arterial hypertension (PAH) medication is on track to be the company's next blockbuster drug, already delivering $419 million in sales in just the first two ...

In 2024, the FDA approved Merck's drug sotatercept-csrk (U.S. brand name: WINREVAIR, for injection, 45mg, 60mg) for treating adults with pulmonary arterial hypertension. This drug helps improve ...

Its blockbuster cancer drug, Keytruda, continues to be a significant growth driver, and the launch of Winrevair has further boosted revenues. While short-term volatility persists, Merck remains a ...

Aside from subcutaneous Keytruda, Merck is leaning on its pulmonary hypertension therapy Winrevair, which according to William Blair will be the pharma’s “main driver of growth,” expecting $4.9 ...

New Jersey’s life sciences community is celebrating another year of groundbreaking medical advancements from the scores of pharmaceutical companies headquartered across the state. As part of ...